6-[ 18 F]-Fluoro-L-dopa (FDOPA) has been widely used as a biomarker for catecholamine synthesis, storage, and metabolism-its intense uptake in the striatum, and fainter uptake in other brain regions, is correlated with the symptoms and pathophysiology of Parkinson's disease (PD). 6-[ 18 F]fluoro-m-tyrosine (FMT), which also targets L-amino acid decarboxylase, has potential advantages over FDOPA as a radiotracer because it does not form catechol-O-methyltransferase (COMT) metabolites. The purpose of the present study was to compare the regional distribution of these radiotracers in the brains of PD patients. Fifteen Parkinson's patients were studied with FMT and FDOPA positron emission tomography (PET) as well as high-resolution structural magnetic resonance imaging (MRI). MRI's were automatically parcellated into neuroanatomical regions of interest (ROIs) in Freesurfer (http://surfer.-nmr.mgh.harvard.edu); region-specific uptake rate constants (K occ ) were generated from coregistered PET using a Patlak graphical approach. The essential findings were as follows: (1) regional K occ were highly correlated between the radiotracers and in agreement with a previous FDOPA studies that used different ROI selection techniques; (2) FMT K occ were higher in extrastriatal regions of relatively large uptake such as amygdala, pallidum, brainstem, hippocampus, entorhinal cortex, and thalamus, whereas cortical K occ were similar between radiotracers; (3) while subcortical uptake of both radiotracers was related to disease duration and severity, cortical uptake was not. These results suggest that FMT may have advantages for examining pathologic changes within allocortical loop structures, which may contribute to cognitive and emotional symptoms of PD. Synapse 68:325-331,
INTRODUCTION

6-[
18 F]-Fluoro-L-dopa (FDOPA) is a radiopharmaceutical that follows the metabolic pathway of L-dopa (Brown et al., 1999b) . In catecholaminergic neurons, FDOPA is decarboxylated by aromatic L-amino acid decarboxylase (AAAD) to fluorodopamine, which is taken up into synaptic vesicles by vesicular monoamine transporter type 2 (VMAT2) and cleared from the synaptic cleft by dopamine transporters (DAT; Endres et al., 1997) . Specific uptake of FDOPA in the striatum as measured by positron emission tomography (PET) has been correlated with pathophysiology, duration, and functional status in Parkinson's disease ). In addition to motor symptoms, PD patients suffer from cognitive and emotional symptoms that are not fully explained by nigrostriatal pathology. The ventral tegmental area (VTA) is relatively preserved in PD and contributes dopaminergic projections to many brain regions outside the striatum; several studies have related this extrastriatal uptake to non-motor symptoms (Bruck et al., 2005; Rinne et al., 2000) .
Quantitation of FDOPA uptake is limited by the formation of catechol-O-methyltransferase (COMT) metabolites that decrease signal to background (DeJesus, 2003) . For extrastriatal tissue, this is especially problematic, as specific uptake in many of these regions may be too low to be accurately measured by PET (Brown et al., 1999b) . 6-[
18 F]fluoro-m-tyrosine (FMT), which also targets AAAD, has characteristics that potentially increase its sensitivity as a radiotracer; it has a 10-fold greater affinity for AAAD and is not a substrate for COMT. FMT and its metabolites also have poor affinity for DAT and VMAT2 (DeJesus, 2003) .
Few studies have compared FMT to FDOPA as tools to study extrastriatal uptake; furthermore, many studies of extrastriatal FDOPA uptake have been done using normalized brain images. Since these studies were done, Freesurfer (http://surfer. nmr.mgh.harvard.edu) has been developed as a reliable tool for standard magnetic resonance imaging (MRI)-based cortical parcellation in native space. The goals of the present study were to compare the uptake profiles of FMT and FDOPA within Freesurfer-defined regions of interest (ROIs), to rank regional uptake values in comparison to previous studies, and to relate regional uptake to disease duration and severity of clinical symptoms.
MATERIALS AND METHODS
Fifteen subjects (mean age 60.3 years; SD, 6 years; 12 men) with Hoehn and Yahr stage 1-3 Idiopathic Parkinson Disease (PD) by UK brain bank criteria (Gibb and Lees, 1988) , normal liver function, and absence of other major disease, were recruited from local movement disorders clinics. Of these subjects, five were taking monoamine oxidase inhibitors (MAOIs), seven were taking dopamine agonists (pramipexole or ropinerole), and three were taking carbidopa/levodopa (750-1200 mg of levodopa daily).
Procedures included brain FDOPA and FMT PET imaging, magnetic resonance imaging (MRI), and Unified Parkinson Disease Rating Scale (UPDRS; Fahn et al., 1987) scoring by a movement disorders specialist (CG). Subjects were off anti-Parkinson medication for 18 hours prior to PET and UPDRS scoring. The local institutional review board approved the protocol, and informed consent was obtained from all participants.
FDOPA and FMT were synthesized by electrophilic fluorination of the appropriate stannylated precursors [for FMT, N-(trifluoroacetyl)-3-acetoxy-6-(trimethylstannyl)-l-phenylalanine ethyl ester (ABX, Radeberg, Germany)] followed by flash chromatography over alumina, hydrolysis in HBr, separation by semi-prep HPLC and final workup to radiopharmaceutical purity (Namavari et al., 1993; Nickles et al., 1984) .
Subjects were pretreated with carbidopa, 2.5 mg/kg orally prior to each PET scan, and 200 mg tolcapone (a COMT inhibitor) prior to the FDOPA scan. These pretreatment doses were given a mean of 59 (range 47-75, SD 9) minutes before the FDOPA scan and 65 (range 50-74, SD 7) minutes before the FMT scan. Since tolcapone has in rare cases been associated with liver damage (Keating and Lyseng-Williamson, 2005) , serum AST, an index of liver function, was acquired at study enrollment and 2-4 weeks after the tolcapone dose.
PET images were obtained on a Siemens ECAT EXACT HR1 PET scanner with an axial intrinsic resolution of 4.7 mm. Following intravenous injection of 5.2 mCi 6 10% of radiopharmaceutical, 18 3D dynamic frames were acquired over 90 minutes. The mean within-subject difference in injected activity of FMT and FDOPA was 2%. The mean interval between FMT and FDOPA PET scans was 35 days.
MRI scans were obtained on a 3T GE SIGNA scanner using an 8-channel head coil, with higher-order shimming. A magnetization-prepared rapid gradient echo (MPRAGE) T1-weighted volume (TR 6.6 For PET image analysis, FDOPA and FMT PET sinograms were reconstructed by filtered backprojection into 18 volumes (time frames), each containing 128 3 128 3 63, 1.84 3 1.84 3 2.43 mm voxels, corrected for scatter, attenuation, and F-18 decay. Each frame was realigned, within-subject, to the total sum image of the FDOPA study. The FDOPA sum image was then coregistered to the T1-weighted MRI scan using a 12-degree affine transformation in SPM8 (www.fil.ion.ucl.ac.uk/spm). This transformation was then applied to each of the FDOPA and FMT volumes, resampling them to the 1 3 1 3 1 mm FreeSurfer resolution using a 7th degree B-Spline interpolation. Mean time-activity curves (TAC) were extracted from the coregistered PET time series for each Freesurfer ROI as defined by the Desikan et al. (2006) cortical and Fischl (2002) subcortical labeling systems. Occipital cortex TAC's were derived from hand-drawn volumes of 11,378 (SD 2284) mm 3 . These Freesurfer-defined ROI and occipital reference tissue TAC's were used to derive a normalized tissue uptake rate constant (K occ ) using Patlak analysis (Patlak and Blasberg, 1985) . An overview of the method is shown in Figure 1 . Since uptake within right and left ROIs was similar, K occ were averaged across hemispheres.
Statistical analyses of the ROI K occ values were conducted in SPSS (Version 21, IBM, Chicago). ROIs whose K occ did not differ from zero by one-sample ttest (P < 0.05) were removed from further analysis. These regions of very low uptake were the frontal pole; rostral and caudal middle frontal gyrus; postcentral gyrus; superior and inferior parietal cortex; cingulate isthmus; precuneus and cuneus; pericalcarine cortex; and lingual gyrus. . 4D PET were coregistered within-subject to the MRI (middle left) and mean time-activity curve (TAC) extracted within each MRI-defined region (bottom left). The tissue-derived uptake rate constant (K occ ) was generated using Patlak analysis from the TAC for each region and that of the occipital reference region (bottom left). The region shown as an example (middle left and right) is the superior frontal cortex.
Synapse
The 26 retained ROIs were then ranked by K occ and ROI/putamen ratios calculated for each ROI and radiotracer. Bivariate (Pearson) correlations were used to compare the ranks and K occ values between FDOPA and FMT, and with anatomically similar regions reported in the literature. To explore autocorrelation in the PET dataset and to develop representative indices for comparison with clinical data, a factor analyses (by principal components) was conducted for each radiotracer on the 26 ROI K occ values. Based on these PCA analyses and related correlation matrix, we generated an index of subcortical uptake by averaging highly correlated (r 5 0.6-0.9) K occ values from amygdala, caudate nucleus, nucleus accumbens, putamen, pallidum, and brainstem, and a cortical index by averaging K occ for the remaining ROIs with correlated uptake values (r 5 0.6-0.9). Disease duration and total UPDRS scores were then compared with these indices using partial correlations controlling for age.
RESULTS
ROI's are ranked by K occ in Figure 2 . Both K occ values and rankings were highly correlated between radiotracers (r 5 0.98 and 0.90, respectively), with the exception of thalamic and brainstem uptake, which was higher for FMT than FDOPA. Regional uptake values were roughly proportionate to those described in previous studies, in spite of differences in region selection technique (Table I ). For example, Moore et al. (2008) measured FDOPA K occ within handrefined regions analogous to 13 of the Freesurfer ROIs, deriving proportionate K occ values ( Fig. 3 ; r 5 0.87).
While subcortical uptake was higher for FMT, cortical K occ was similar between radiotracers, yielding higher ROI/putamen ratios for FDOPA. For cortical ROIs, mean ROI/putamen K occ ratio was 0.18 (SD 0.21) for FDOPA and 0.12 (SD 0.12) for FMT. FMT K occ /FDOPA K occ was >1 in subcortical ROIs such as amygdala, thalamus, and brainstem, as well as anterior and posterior cingulate cortex, precentral gyrus, entorhinal cortex, and hippocampus; this ratio was 1 for the remainder of cortical ROIs.
The exploratory factor analysis of 26 regional K occ values yielded a principal component that was correlated with cerebral cortical and hippocampal uptake (r 5 0.65-0.88), and explained 40-42% of the variance, a subcortical component correlated with nucleus accumbens, caudate nucleus, putamen, amygdala, pallidum, and brainstem uptake (r 5 0.41-0.85) that explained 20-22% of the variance, and minor components. Based on these analyses, cortical and subcortical indices were generated (see "methods"). Partial correlations, controlling for age, showed that the subcortical index declined with disease duration (FMT partial correlation coefficient, pr 5 -0.86; FDOPA pr 5 -0.70; 2-tailed P < 0.01), but that the cortical index did not (Fig. 4) . K occ within individual extrastriatal, sub-cortical structures such as the amygdala (FDOPA pr 5 -0.69; 2-tailed P < 0.01) and pallidum (FMT pr 5 -0.90; 2-tailed P < 0.001) were also related to disease duration. UPDRS total scores were inversely correlated with the subcortical 
DISCUSSION
This is one of the first human studies to compare extrastriatal uptake between FMT and FDOPA. As was seen in a similar study of three non-human primates (Brown et al., 1999a) , regional uptake rate constants were higher for FMT in regions of high/specific uptake, but similar or indistinguishable between tracers in regions of low uptake. Unfortunately the study design, which did not include control subjects, precludes comment on the relative sensitivity of the two tracers. Regional uptake values and ranks were highly correlated between the radiotracers and largely in agreement with previous FDOPA rankings in Parkinson's and normal subjects, in spite of differences in ROI selection technique (Table I, Fig. 3 ; Moore et al., 2008 Moore et al., , 2003 . The narrow Freesurferdefined ROI's ( Fig. 1 ) generated lower FDOPA K occ values than reported in some previous investigations (Moore et al., 2008) but similar to others (Kaasinen et al., 2001; Nagano et al., 2000) .
In (non-PD) post-mortem brains, concentrations of dopamine and noradrenaline are highest in hippocampus, followed by anterior cingulate, entorhinal, and dorsolateral prefrontal cortex; concentrations in PD brains are 2-3 fold lower (Scatton et al., 1983) . It is encouraging that the order of ROI's ranked by K occ in the present study is roughly commensurate with relative catecholamine concentrations reported by Scatton et al. The amygdala, entorhinal cortex, and hippocampal formation participate in an allocortical loop that funnels sensory information into limbic circuits and projects to the ventral striatum; pathologic involvement of brain structures in this pathway is thought to underlie emotional symptoms of PD (Braak et al., 1995) . Therefore, a reliable system for quantifying AAAD activity in these regions holds promise for the study of non-motor symptoms in vivo.
In a study of normal subjects, Brown et al. (1999b) calculated regional FDOPA uptake as a percentage of putamen uptake: Amygdala 35% (current study FDOPA, FMT both 80%); hippocampus 30% (current study, FDOPA 22%, FMT 32%); frontal and temporal cortices 10-15% (current study FDOPA 10-25%, FMT 4-9%); and anterior cingulate 20% (current study FDOPA 23%, FMT 21%). A comparison of these ratios between normal and PD subjects suggests that amygdala K occ is preserved relative to putamen in early PD. This is consistent with previous reports of increased FDOPA uptake in the amygdala, as well as pallidum, dorsolateral prefrontal, and anterior cingulate cortex, in early Parkinson's disease (Brooks and Piccini, 2006; Bruck et al., 2005; Kaasinen et al., 2001; Rakshi et al., 1999) .
Although FMT K occ exceeded FDOPA K occ in regions of high/specific uptake, K occ was similar between tracers in the cerebral cortex. This effect probably occurs because in regions of very low uptake, the ROI TAC resembles that of the reference region (See Fig. 1 for example), producing a "floor effect" for the accurate measurement of K occ . Nonetheless, we did eliminate regions for which measurement error rendered K occ indistinguishable from zero. Therefore, the relatively high FDOPA K occ in cortical regions may reflect differences in the metabolism and trapping of the radiotracers, as well as effects of COMT inhibition on FDOPA trapping. The uptake rate constant reflects the amount of tracer accumulated in regions of specific trapping relative to the cumulative exposure of these regions to the tracer circulating in the plasma; when using a tissue input function for the Patlak analysis, the presence of circulating metabolite in the reference region leads to an overestimate of the amount of tracer available for trapping, lowering K occ . Tolcapone reduces circulating metabolites, thus increasing FDOPA K occ , (but not K i , which is calculated using a metabolite-corrected input function) (Doudet et al., 1997; Ruottinen et al., 1997) . In previous work, we estimated peripheral COMT inhibition in the current study to be as high as 80% (Gallagher et al., 2011) . COMT is highly expressed in frontal cortex, and its inhibition has been shown to increase synaptic dopamine in these regions, thus influencing dopamine-dependent executive functions (Apud and Weinberger, 2007) . The factor analysis and related correlation matrices suggested that regional K occ values fell primarily into cortical and subcortical components that differed in their relationship to disease duration and severity. In the brain, cells that synthesize dopamine are located in the substantia nigra (SN), ventral tegemental area (VTA), and neurohypophyseal system. The VTA sends projections through several pathways to cortical and subcortical structures: Mesocortical projections to the prefrontal cortex and insula; mesolimbic projections to the nucleus accumbens, amygdala, hippocampus, entorhinal cortex, anterior cingulate cortex, and claustrum; mesostriatal projections to the anteromedial striatum; mesodiencephalic projections to several thalamic nuclei as well as hypothalmaus; and mesorhombencephalic projections to superior colliculus, reticular formation, periaqueductal grey, and spinal cord (Oades and Halliday, 1987) . Although the VTA is relatively preserved in PD in comparison to the SN, pathological studies have shown both pathways to be affected (Braak et al., 1995) . Differential vulnerability of SN versus VTA dopaminergic projections may partially explain why cortical and subcortical uptakes were not well correlated.
We observed that disease duration and severity (UPDRS scores) were related to subcortical uptake of both tracers, but showed little relationship to cortical uptake. Both pathologic and imaging investigations have suggested that extrastriatal catecholamine levels are lower than normal in PD (Moore et al., 2008; Scatton et al., 1983) . Longitudinal studies have shown progressive decline in FDOPA uptake within extrastriatal structures (locus ceruleus, pallidum, hypothalamus, midbrain raphe) over 3 years in PD (Pavese et al., 2011 )-however, decline in cortical regions was not described. In PD patients treated with L-dopa, there is a progressive decline in D2 receptor availability in anterior cingulate, dorsolateral prefrontal, and temporal cortex, as well as thalamic regions, with disease progression (Kaasinen et al., 2003) . Based on these previous investigations as well as findings from the present study, we hypothesize that progressive decline in uptake of dopamine radiotracers will be detected in extrastriatal regions of high specific uptake (such as amygdala) with disease progression, but that decline in cortical regions will not be detectable.
Neither FMT nor FDOPA provided advantage for the study of cortical regions; however, FMT may have advantages for quantification of AAAD activity in extrastriatal regions of relatively high specific uptake such as amygdala, pallidum, thalamus, anterior cingulate cortex, entorhinal cortex, and hippocampus. The cognitive and emotional symptoms of PD may be related to radiotracer loss within these allocortical structures. A larger, longitudinal study will be needed to definitively investigate these hypotheses.
